Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 6/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 4/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609569 | 0.98 | CYP11B1 (0.43) | CYP11B1CYP11B2CHRM2CHRM4CHRM5 | |
| SCHEMBL7611053 | 0.76 | MPI (0.41) | CYP11B1CYP11B2CYP17A1CYP1A2CYP2E1 | |
| SCHEMBL29988790 | 0.69 | TDO2 (0.49) | CYP11B1CYP11B2CYP17A1CYP1A2CYP2E1 | |
| SCHEMBL3421743 | 0.69 | TDO2 (0.49) | CYP11B1CYP11B2CYP17A1CYP1A2CYP2E1 | |
| SCHEMBL3570023 | 0.66 | CYP11B1 (0.46) | CYP11B1CYP11B2CYP17A1CYP1A2PDE2A | |
| SCHEMBL22828751 | 0.62 | CYP2A6 (0.59) | CYP11B1CYP11B2CYP17A1CYP1A2CYP2A6 | |
| SCHEMBL828082 | 0.62 | — | — | |
| SCHEMBL30824501 | 0.62 | — | — | |
| SCHEMBL14900842 | 0.62 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP17A1CYP1A2CYP2E1 | |
| SCHEMBL19059572 | 0.62 | CYP17A1 (0.46) | CYP11B1CYP11B2CYP17A1CYP1A2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0734259-B1 | Use of piperidine compounds in the treatment of schizophrenia | NOVO NORDISK AS (DK) | 2002-06-12 | — | — | EP | disclosed |
| US-5773452-A | ALZHEIMER'S DISEASE; COGNITION ACTIVATORS | NOVO NORDISK ALS (DK) | 1998-06-30 | — | — | US | disclosed |
| US-5753683-A | SCHIZOPHRENIA | NOVO NORDISK A/S (DK) | 1998-05-19 | — | — | US | disclosed |
| US-5750541-A | 3-(1,2,5-THIA OR OXADIAZOL-3-YL)-1,2,5,6-PYRIDINE DERIVATIVES; SCHIZOPHRENIFORM DISEASES; SIDE EFFECT REDUCTION | NOVO NORDISK A/S (DK) | 1998-05-12 | — | — | US | disclosed |
| US-5744489-A | ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS | GREENWOOD BEVERLEY (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0788357-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1997-08-13 | — | — | EP | disclosed |
| US-5591755-A | Pyridinyl thiadiazolyl compounds for treating glaucoma | NOVO NORDISK A/S (DK) | 1997-01-07 | — | — | US | disclosed |
| US-5565475-A | Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives | MUHLHAUSER MARK A (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0734259-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1996-10-02 | — | — | EP | disclosed |
| EP-0732925-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1996-09-25 | — | — | EP | disclosed |
| US-5545638-A | USING A 3-(TETRAHYDROPYRID-3-YL-) SUBSTITUTED (OXA- OR THIA-)DIAZOLE COMPOUND | NOVO NORDISK A/S (DK) | 1996-08-13 | — | — | US | disclosed |
| WO-1996014066-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1996-05-17 | — | — | WO | disclosed |
| EP-0687265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-12-20 | — | — | EP | disclosed |
| EP-0544714-B1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1995-11-22 | — | — | EP | disclosed |
| WO-1995017185-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995005174-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | disclosed |
| WO-1994020495-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-09-15 | — | — | WO | disclosed |
| US-5328923-A | Compounds contain tetrahydropyridine ring and thiadiazole ring, Alzheimer*s disease, glaucoma, pain relief | NOVO NORDISK A/S (DK) | 1994-07-12 | — | — | US | disclosed |